The degradation of PML-RARα can be induced by pharmacological doses of all-trans retinoic acid (ATRA), thereby enabling transcription and terminal differentiation of immature precursor cells.2 However, ATRA is only clinically successful for the small subset of APL patients. The gene discussed is RARA; the disease is acute promyelocytic leukemia.